Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. [electronic resource] by
- Floc'h, Nicolas
- Martin, Matthew J
- Riess, Jonathan W
- Orme, Jonathan P
- Staniszewska, Anna D
- Ménard, Ludovic
- Cuomo, Maria Emanuela
- O'Neill, Daniel J
- Ward, Richard A
- Finlay, M Raymond V
- McKerrecher, Darren
- Cheng, Mingshan
- Vang, Daniel P
- Burich, Rebekah A
- Keck, James G
- Gandara, David R
- Mack, Philip C
- Cross, Darren A E
Producer: 20190708
In:
Molecular cancer therapeutics vol. 17
Availability: No items available.
|